Xenon Pharmaceuticals Financial Ratios
NASDAQ: XENEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
36.44+0.28 (+0.77%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Xenon Pharmaceuticals ratio analysis
Xenon Pharmaceuticals earned a net margin of -4612.1% in FY 2025. Return on equity reached -59.5%, meaning Xenon Pharmaceuticals generated -0.59 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Xenon Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 470.13 | — | — | 253.04 | 73.92 | 16.52 | 50.33 | — | 163.37 | 66.17 |
| Price / book | 6.06 | 4.18 | 3.32 | 3.31 | 2.48 | 3.10 | 3.74 | 1.29 | 1.41 | 1.87 |
| Operating margin | -4,974.3% | — | — | -1,368.9% | -428.4% | -97.3% | -627.0% | — | -10,474.3% | -1,376.4% |
| Net margin | -4,612.1% | — | — | -1,328.9% | -427.8% | -89.7% | -609.1% | — | -9,872.7% | -1,275.5% |
| Free cash flow margin | -3,732.2% | — | — | -1,101.6% | -388.1% | -157.8% | -87.2% | — | -9,337.9% | -1,100.7% |
| Return on equity (ROE) | -59.5% | -31.0% | -19.7% | -17.4% | -14.3% | -16.8% | -45.2% | -33.4% | -85.4% | -36.0% |
| Return on assets (ROA) | -54.6% | -29.4% | -18.9% | -16.6% | -13.8% | -15.2% | -28.2% | -28.2% | -66.6% | -34.1% |
| Debt / equity | — | — | — | — | — | — | 0.17 | 0.15 | 0.19 | — |
| Current ratio | 13.42 | 17.85 | 23.65 | 26.44 | 39.03 | 12.30 | 3.34 | 29.46 | 10.98 | 18.31 |
| Revenue growth | — | — | -100.0% | -48.8% | -42.7% | 371.0% | — | — | -82.8% | -88.4% |